POZNÁMKY

1. kapitola: Chýbajúce údaje

1. Bourgeois F. T., Murthy S., Mandl K. D. Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov. Annals of Internal Medicine. 2010; 153(3):158–66.
2. Bero L., Oostvogel F., Bacchetti P., Lee K. Factors Associated with Findings of Published Trials of Drug–Drug Comparisons: Why Some Statins Appear More Efficacious than Others. PLoS Med. 5. jún 2007; 4(6):e184.
3. Kelly R. E. Jr., Cohen L. J., Semple R. J., Bialer P., Lau A., Bodenheimer A., et al. Relationship between drug company funding and outcomes of clinical psychiatric research. Psychol Med. November 2006; 36(11):1647–56.
4. Bekelman J. E., Li Y., Gross C. P. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289:454–65. Lexchin J., Bero L. A., Djulbegovic B., Clark O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326:1167–70.
5. Sergio S. Pharmaceutical company funding and its consequences: A qualitative systematic review. Contemporary Clinical Trials. Marec 2008; 29(2):109–13.
6. Eyding D., Lelgemann M., Grouven U., Harter M., Kromp M., Kaiser T., et al. Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials. BMJ. 12. október 2010; 341:c4737–c4737.
7. Suntharalingam G., Perry M. R., Ward S., Brett S. J., Castello-Cortes A., Brunner M. D., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 7. september 2006; 355(10):1018–28.
8. Expert Group on Phase One Clinical Trials: Final report [Internet]. 2006 [citované 5. apríla 2012]. Dostupné na: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_063117

9. Decullier E., Chan A.-W., Chapuis F. Inadequate Dissemination of Phase I Trials: A Retrospective Cohort Study. PLoS Med. 17. február 2009; 6(2):e1000034.
10. Cowley A. J., Skene A., Stainer K., Hampton J. R. The effect of lorcainide on arrhythmias and survival in patients with acute myocardial infarction: an example of publication bias. International journal of cardiology. 1993; 40(2):161–6. Iain Chalmers bol prvý, kto upozornil na TGN1412 a antiarytmické lieky ako príklady škôd spôsobené tým, že jednotlivé rané výskumy neboli publikované. Sú to najlepšie ilustrácie daného problému, ale nemali by ste si predstavovať, že sú nejako neobvyklé. Kvantitatívne dáta ukazujú, že sú to len dva z mnohých, mnohých podobných prípadov.
11. Antman E. M., Lau J., Kupelnick B., Mosteller F., Chalmers T. C. A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. JAMA. 8. júl 1992; 268(2):240–8.
12. Tu je klasický raný článok, ktorý sa zaoberá touto otázkou: Chalmers Iain. Underreporting Research Is Scientific Misconduct. JAMA. 9. marec 1990; 263(10):1405–1408.
13. Sterling T. Publication decisions and their possible effects on inferences drawn from tests of significance – or vice versa. Am Stat Assoc J 1959;54:30–4.
14. Sterling T. D., Rosenbaum W. L., Weinkam J. J. Publication decisions revisited – the effect of the outcome of statistical tests on the decision to publish and vice-versa. Am Stat 1995; 49:108–12.
15. Bacon F. (1645). Franc Baconis de Verulamio/Summi Angliae Cancellarii/Novum organum scientiarum. [Francis Bacon of St. Albans Lord Chancellor of England. A 'New Instrument' for the sciences] Lugd. Bat: apud Adrianum Wiingaerde, et Franciscum Moiardum. Aphorism XLVI (str. 45–46).
16. Fowler T. (1786). Medical reports of the effects of arsenic in the cure of agues, remitting feveres and periodic headaches. London: J Johnson, str. 105–107.
17. Hemminki E. Study of information submitted by drug companies to licensing authorities. Br Med J. 22. marec 1980; 280(6217):833–6.
18. Lee K., Bacchetti P., Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med 2008; 5(9):e191.

19. Melander H., Ahlqvist-Rastad J., Meijer G., Beermann B. Evidence b (i) ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003; 326:1171–3.
20. Rising K., Bacchetti P., Bero L. Reporting Bias in Drug Trials Submitted to the Food and Drug Administration: Review of Publication and Presentation. PLoS Med. 25. november 2008; 5(11):e217.
21. Scherer R. W., Langenberg P., von Elm E. Full publication of results initially presented in abstracts. Cochrane Database Syst Rev 2007; 2: MR000005.
22. Song F., Parekh S., Hooper L., Loke Y. K., Ryder J., Sutton A. J., et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. Február 2010; 14(8): iii, ix–xi, 1–193.
23. Dickersin K. How important is publication bias? A synthesis of available data. Aids Educ Prev 1997; 9(1 SA):15–21.
24. Ioannidis J. Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. JAMA 1998; 279:281–6.
25. Bardy A. H. Bias in reporting clinical trials. Brit J Clin Pharmaco 1998; 46:147–50.
26. Dwan K., Altman D. G., Arnaiz J. A., Bloom J., Chan A. W., Cronin E., et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 2008; 3(8):e3081.
27. Decullier E., Lhéritier V., Chapuis F. Fate of biomedical research protocols and publication bias in France: retrospective cohort study. BMJ 2005; 331:19. Decullier E., Chapuis F. Impact of funding on biomedical research: a retrospective cohort study. BMC Public Health 2006; 6:165.
28. Cronin E., Sheldon T. Factors influencing the publication of health research. Int J Technol Assess 2004 ;20:351–5.
29. Song F., Parekh S., Hooper L., Loke Y. K., Ryder J., Sutton A. J., et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. Február 2010; 14(8):iii, ix–xi, 1–193.
30. Na tento problém ako prvý upozornil Jamie Heywood z PatientsLiekMe, ktorý strávil dlhý čas nad mnohými pokusmi a omylmi pri zdrojoch, aby replikoval výskumné zistenia v inej oblasti medicíny. Pri poslednom stretnutí sme hovorili o zapísaní jeho myšlienky, že pravdepodobnosť, že je nejaké tvrdenie pravdivé, je priamo úmerná

nákladom vynaloženým na jeho prezentovanie a naopak nepriamo úmerná nákladom vynaloženým na jeho vyvrátenie. Neurobili sme to a dokiaľ to neurobíme, bude popis našej konverzácie jediným dôkazom tejto zaujímavej myšlienky.
31. Begley C. G., Ellis L. M. Drug development: Raise standards for preclinical cancer research. Nature. 28. marec 2012; 483(7391):531–3.
32. Harrabin R. et al. (2003). Health In The News, The King's Fund, London, UK.
33. Forsyth, Alasdair J. M. 2001. Distorted? a quantitative exploration of drug fatality reports in the popular press. International Journal of Drug Policy 12, no. 5–6 (November 1): 435–453.
34. Dickersin K., Min Y. I., Meinert C. L.: Factors influencing publication of research results: follow-up of applications submitted to two institutional review boards. JAMA 1992, 267:374–378.
35. Olson C. M., Rennie D., Cook D., Dickersin K., Flanagin A., Hogan J. W., Zhu Q., Reiling J., Pace B.: Publication bias in editorial decision making. JAMA 2002, 287:2825–2828.
36. Lee K. P., Boyd E. A., Holroyd-Leduc J. M., Bacchetti P., Bero L. A. Predictors of publication: characteristics of submitted manuscripts associated with acceptance at major biomedical journals. Med J Aust 2006; 184:621–6. Lynch J. R., Cunningham M. R. A., Warme W. J., Schaad D. C., Wolf F. M., Leopold S. S. Commercially funded and United States-based research is more likely to be published; good-quality studies with negative outcomes are not. J Bone Joint Surg Am 2007; 89:1010–8. Okike K., Kocher M. S., Mehlman C. T., Heckman J. D., Bhandari M. Publication bias in orthopaedic research: an analysis of scientific factors associated with publication in the Journal of Bone and Joint Surgery. J Bone Joint Surg Am 2008; 90:595–601.
37. Epstein W. M. Confirmation response bias among social work journals. Sci Techol Hum Values 1990; 15:9–38.
38. Mahoney M. J. Publication prejudices: an experimental study of confirmatory bias in the peer review system. Cognitive Ther Res 1977; 1:161–75.
39. Ernst E., Resch K. L. Reviewer bias – a blinded experimental study. J Lab Clin Med 1994; 124:178–82.
40. Abbot N. E., Ernst E. Publication bias: direction of outcome less important than scientific quality. Perfusion 1998; 11:182–4.
41. Emerson G. B., Warme W. J., Wolf F. M., Heckman J. D., Brand R. A., Leopold S. S. Testing for the Presence of Positive-Outcome Bias in Peer

Review: A Randomized Controlled Trial. Arch Intern Med. 22. november 2010; 170(21):1934–9.
42. Weber E. J., Callaham M. L., Wears R. L., Barton C., Young G. Unpublished research from a medical specialty meeting: why investigators fail to publish. JAMA 1998; 280:257–9.
43. Kupfersmid J., Fiala M. A survey of attitudes and behaviors of authors who publish in psychology and education journals. Am Psychol 1991; 46:249–50.
44. Song F., Parekh S., Hooper L., Loke Y. K., Ryder J., Sutton A. J., et al. Dissemination and publication of research findings: an updated review of related biases. Health Technol Assess. Február 2010; 14(8):iii, ix–xi, 1–193.
45. Gøtzsche P. C., Hróbjartsson A., Johansen H. K., Haahr M. T., Altman D. G., Chan A.-W.: Constraints on publication rights in industry-initiated clinical trials. JAMA 2006, 295:1645–1646.
46. Gornall, J. 'Industry attack on academics.' BMJ 338, no. mar09 1 (9. marec 2009): b736–b736.
47. Tamtiež.
48. Steinbrook R. Gag clauses in clinical-trial agreements. N. Engl. J. Med. 26. máj 2005; 352(21):2160–2.
49. Mello M. M., Clarridge B. R., Studdert D. M. Academic medical centers' standards for clinical-trial agreements with industry. N. Engl. J. Med. 2005; 352(21):2202.
50. Toto je jeden z mnohých príbehov, kde odporúčam ponoriť sa do hroznych podrobností, ak vás to zaujíma. Dobrým miestom, kde začať, je blog prof. Davida Colquhouna na túto tému s mnohými odkazmi: http://www.dcscience.net/?p=193 a tento článok v BMJ napísaný právnikom, aby som im urobil radosť, keď čítajú túto knihu: Dyer C. Aubrey Blumsohn: Academic who took on industry. BMJ. 2009 Dec 15; 339 (dec15 1):b5293–b5293.
51. Wendler D., Krohmal B., Emanuel E. J., Grady C., pro ESPRIT Group. Why Patients Continue to Participate in Clinical Research. Arch Intern Med. 23. jún 2008; 168(12):1294–9.
52. McDonald A. M., Knight R. C., Campbell M. K., Entwistle V. A., Grant A. M., Cook J. A., et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006; 7:9.
53. Simes R. J. Publication bias: the case for an international registry of clinical trials. Journal of Clinical Oncology. 1. október 1986; 4(10):1529–1541.

54. Clarke M., Clarke L., Clarke T. Yes Sir, no Sir, not much difference Sir. JRSM. 1. december 2007; 100(12):571–572.
55. Chalmers Iain. Underreporting Research Is Scientific Misconduct. JAMA: The Journal of the American Medical Association. 9. marec 1990; 263(10):1405–1408.
56. Chalmers I. From optimism to disillusion about commitment to transparency in the medico-industrial complex. JRSM. 1. júl 2006; 99(7):337–341.
57. Ich delegáciu viedol Frank Wells: jeho učebnica o podvodoch je fantastická. Hovorím vám to len preto, aby ste pochopili, že to nie sú všetko len zlí ľudia s povahou, ktorá je vo svojej podstate tajnostkárska.
58. Sykes R. Being a modern pharmaceutical company. BMJ. 31. október 1998; 17(7167):1172–80.
59. De Angelis C., Drazen J. M., Frizelle F. A., Haug C., Hoey J., Horton R., et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. The Lancet. 11. september 2004; 364(9438):911–2.
60. Mathieu S., Boutron I., Moher D., Altman D. G., Ravaud P. Comparison of Registered and Published Primary Outcomes in Randomized Controlled Trials. JAMA. 2. september 2009; 302(9):977–84.
61. Wieseler B., McGauran N., Kaiser T. Still waiting for functional EU Clinical Trials Register. BMJ. 20. jún 2011; 342 (jun202):d3834–d3834.
62. Prayle A. P., Hurley M. N., Smyth A. R. Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ. 2012; 344:d7373.
63. Dobrý, aj keď stručný prehľad o tom, ako sa pokúsiť a získať informácie z neakademických zdrojov, je tu: Chan A.-W. Out of sight but not out of mind: how to search for unpublished clinical trial evidence. BMJ. 3. január 2012; 344(jan03 2):d8013–d8013.
64. Listy aj správu si môžete prečítať on-line. Ide o pútavé čítanie s mnohými zaujímavými a ohavnými podrobnosťami, takže vám vrelo odporúčam prečítať si to: Medicines and Healthcare products Regulatory Agency (MHRA) www. mhra. gov. u. GSK investigation concludes [Internet]. [citované 29. apríla 2012]. Dostupné na: http://www.mhra.gov.uk/Howweregulate/Medicines/Medicinesregulatorynews/CON014153
65. Bola to firma SmithKline Beecham, neskôr sa spojila s GlaxoWellcome a stala sa GSK.

66. Lenzer J., Brownlee S. Antidepressants: an untold story? BMJ 2008; 336:532–4.
67. Wood A. J. Progress and deficiencies in the registration of clinical trials. N Engl J Med. 2009; 360(8):824–830
68. O'Connor A. B. The need for improved access to FDA reviews. JAMA: The Journal of the American Medical Association. 2009; 302(2):191.
69. http://www.prescrire.org/editoriaux/EDI33693.pdf
70. Rozhodnutie Európskeho ombudsmana, ktorým uzavrel svoje vyšetrovanie sťažnosti 2560/2007/BEH proti Európskej agentúre pre liečivá, November 2010: http://www.ombudsman.europa.eu/cases/decision.faces/en/5459/html.bookmark.
71. UK drug regulator destroys all the evidence after 15 years/BMI[Internet]. Dostupné na http://www.bmj.com/rapid-response/2011/11/03/uk-drug-regulator-destroys-all-evidence-after-15-years.
72. Možno vás neprekvapí, ak vám poviem, že v rámci regulácie monitorovania bezpečnosti liekov v UK nebola nikdy žalovaná žiadna veľká farmaceutická firma.
73. Tento príbeh je popísaný v rôznych publikáciách od Cochraneovho tímu a dané vysvetlenie je prevzaté z ich práve publikovaných odpovedí Roche a diskusií s Cochraneovým tímom. Najlepšie miesto, kde sa dozviete prvú polovicu tohto príbehu, je nasledujúci článok: Doshi P. Neuraminidase inhibitors – the story behind the Cochrane review. BMJ. 2009; 339. A na druhú polovicu odporúčam voľne dostupný článok: Doshi P., Jefferson T., Del Mar C. (2012) The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience. PLoS Med 9(4): e1001201. doi:10.1371/journal.pmed.1001201 http://bit.ly/HIbwqO
74. Tu ide o fascinujúcu a chaotickú novú oblasť. Nižšie uvedený článok poskytuje dobrý súhrn o význame analyzovania kompletných výskumných programov aj o rozdieloch nájdených pri Tamiflu medzi jednotlivými článkami a správami o klinických štúdiách: Jefferson T., Doshi P., Thompson M., Heneghan C., Group CARI. Ensuring safe and effective drugs: who can do what it takes? BMJ. 11. január 2011; 342(jan11 1):c7258–c7258.
75. To všetko pochádza z: Jefferson T., Doshi P., Thompson M., Heneghan C., Group CARI. Ensuring safe and effective drugs: who can do what it takes? BMJ. 11. január 2011; 342(jan11 1):c7258–c7258.
76. Tom Jefferson, Lecture on Tamiflu, BMJ Evidence 2011, London.

77. Tramèr M. R., Reynolds D. J., Moore R. A., McQuay H. J. Impact of covert duplicate publication on meta-analysis: a case study. BMJ. 13. september 1997; 315(7109):635–40.
78. Doshi P., Jefferson T., Del Mar C. (2012) The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience. PLoS Med 9(4): e1001201. doi:10.1371/journal.pmed.1001201 http://bit.ly/HIbwqO
79. Cohen D (2009) Complications: tracking down the data on oseltamivir. BMJ 339: b5387.
80. Pokiaľ vás tento príbeh zaujíma, všetky odkazy na primárne dokumenty sú tu: Diabetes drug 'victory' is really an ugly story about incompetence. Ben Goldacre, The Guardian. 17. júl 2010 [citované 2. mája 2012]; Dostupné na: http://www.badscience.net/2010/07/pharmaco-epidemiology-would-be-fascinating-enough-even-if-society--didnt-manage-it-really-really-badly/
81. Nissen S. E. Setting the record straight. JAMA. 24. marec 2010; 303(12):1194–5
82. Eichler H.-G., Abadie E., Breckenridge A., Leufkens H., Rasi G. Open Clinical Trial Data for All? A View from Regulators. PLoS Med. 10. apríl 2012; 9(4):e1001202.
83. Ide o siahodlhý príbeh, ktorý sa dostatočne rozpráva inde. Začnete tu: Curfman G. D., Morrissey S., Drazen J. M. Expression of concern reaffirmed. N. Engl. J. Med. 16. marec 2006; 354(11):1193.
84. Opinion: Misleading Drug Trials. The Scientist [Internet]. [citované 15. mája 2012]. Dostupné na: http://the-scientist.com/2012/05/14/opinion-misleading-drug-trials/
85. Yaleský projekt otvoreného údajového archívu alebo YODA je dobrým príkladom toho, ako by to raz mohlo vyzerať.

2. kapitola: Odkiaľ sa berú nové lieky?

1. Odporúčam klasickú učebnicu pre medikov „Rang and Dale": Rang & Dale's Pharmacology. 6th ed. Churchill Livingstone; 2007. Ale tiež túto prácu o regulačnom procese okolo raného vývoja liekov: Friedhoff L. T. New Drugs: An Insider's Guide to the FDA's New Drug Approval Process for Scientists, Investors and Patients. 1st ed. PSPG Publishing, 2009.

2. Elliott C., Abadie R. Exploiting a research underclass in phase 1 clinical trials. New England Journal of Medicine. 2008; 358(22):2316.
3. Cohen L. P. To screen new drugs for safety, Lilly pays homeless alcoholics: it's 'quick cash' to habitues of Indianapolis shelters; it vanishes quickly, too. Wall St J (East Ed). 14. november 1996; A1, A10.
4. Abadie R. The Professional Guinea Pig: Big Pharma and the Risky World of Human Subjects. 1st ed. Duke University Press, 2010.
5. Helms R., editor. Guinea Pig Zero: An Anthology of the Journal for Human Research Subjects. 1st ed. Garrett County Press; 2006.
6. Tucker T. Great Starvation Experiment: Ancel Keys and the Men Who Starved for Science. 1st University of Minnesota Press Ed. University of Minnesota Press; 2008.
7. Gorkin L., Schron E. B., Handshaw K., Shea S., Kinney M. R., Branyon M., et al. Clinical trial enrollers vs. nonenrollers: The Cardiac Arrhythmia Suppression Trial (CAST) Recruitment and Enrollment Assessment in Clinical Trials (REACT) project. Controlled Clinical Trials. Február 1996; 17(1):46–59.
8. Sheppard V. B., Cox L. S., Kanamori M. J., Cañar J., Rodríguez Y., Goodman M., et al. BRIEF REPORT: If You Build It, They Will Come. J Gen Intern Med. Máj 2005; 20(5):444–7.
9. ACRO – CRO Market [Internet]. [citované 11. februára 2012]. Dostupné na: http://www.acrohealth.org/cro-market1.html.
10. MacDonald T., Hawkey C., Ford I. Time to treat as independent. BMJ. 30. november 2010; 341(nov30 2):c6837–c6837.
11. Kassirer J. On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health. Ch 8. 1st ed. Oxford University Press, USA; 2004.
12. Pharmaceutical CSO – Pharmaceutical Commercialization – Quintiles [Internet.] Dostupné na: http://www.quintiles.com/commercial-services/
13. DRUG TESTING GOES OFFSHORE – 8. august 2005 [Internet]. [citované 11. februára 2012]. Dostupné na: http://money.cnn.com/magazines/fortune/fortune_archive/2005/08/08/8267653/index.htm
14. Thiers F. A., Sinskey A. J., Berndt E. R. Trends in the globalization of clinical trials. Nature Reviews Drug Discovery. Január 2008; 7(1):13–4.
15. Všetky otázky okolo výskumov v rozvojových krajinách sú dobre zdokumentované v dvoch knihách: Shah S. BODY HUNTERS, THE: Testing New Drugs on the World's Poorest Patients. SCIE. THE NEW PRESS; 2007. A Petryna A. When Experiments Travel: Clinical Trials

and the Global Search for Human Subjects. 1st ed. Princeton University Press; 2009.
16. Ethical and Scientific Implications of the Globalization of Clinical Research Seth W. Glickman, M.D., M.B.A., John G. McHutchison, M.D., Eric D. Peterson, M.D., M.P.H., Charles B. Cairns, M.D., Robert A. Harrington, M.D., Rbert M. Califf, M.D., a Kevin A. Schulman, M.D. N Engl J Med 2009; 360:816–823. 19. február 2009.
17. Bansal N. The opportunities and challenges in conducting clinical trials globally. Clinical Research and Regulatory Affairs. 9. február 2012; 1–6.
18. Ethical and Scientific Implications of the Globalization of Clinical Research Seth W. Glickman, M.D., M.B.A., John G. McHutchison, M.D., Eric D. Peterson, M.D., M.P.H., Charles B. Cairns, M.D., Robert A. Harrington, M.D., Robert M. Califf, M.D., a Kevin A. Schulman, M.D. N Engl J Med 2009; 360:816–823. 19. február 2009.
19. Hyder A. A., Wali S. A., Khan A. N., Teoh N. B., Kass N. E., Dawson L. Ethical review of health research: a perspective from developing country researchers. J Med Ethics. 2004 Feb; 30(1):68–72.
20. Zhang D., Yin P., Freemantle N., Jordan R., Zhong N., Cheng K. K. An assessment of the quality of randomised controlled trials conducted in China. Trials. 2008; 9:22.
21. FDA Requires Foreign Clinical Studies be in Accordance with Good Clinical Practice to Better Protect Human Subjects od W. Thomase Smithe – American Bar Association Health eSource, október 2008 roč. 5, číslo 2 [Internet]. [citované 11. februára 2012]. Dostupné na: http://www.americanbar.org/newsletter/publications/aba_health_esource_home/Volume5_02_smith.html
22. Depeša WikiLeaks: Pfizer 'used dirty tricks to avoid clinical trial payout' – Business – The Guardian [Internet]. [citované 11. februára 2012]. Dostupné na: http://www.guardian.co.uk/business/2010/dec/09/wikileaks-cables-pfizer-nigeria
23. Depeša amerického veľvyslanectva, pondelok 20. apríla 2009, 16:00, Abuja 000671 'Pfizer reaches preliminary agreement for $75m settlement' [citované 11. februára 2012]. Dostupné na: http://www.guardian.co.uk/world/us-embassy-cables-documents/203205
24. Depeša WikiLeaks: Pfizer 'used dirty tricks to avoid clinical trial payout' – Business – The Guardian [Internet]. [citované 11. februára 2012]. Dostupné na: http://www.guardian.co.uk/business/2010/dec/09/wikileaks-cables-pfizer-nigeria

25. Jonathan Kimmelman, Charles Weijer a Eric M Meslin, 'Helsinki discords: FDA, ethics, and international drug trials,' The Lancet 373, č. 9657 (3. január 2009): 13–14.
26. Goodyear M. D. E., Lemmens T., Sprumont D., Tangwa G. Does the FDA have the authority to trump the Declaration of Helsinki? BMJ. 21. apríl 2009; 338(apr21 1):b1559–b1559.

3. kapitola: Podivná regulácia liečiv

1. Royal College of Physicians, London UK. INNOVATING FOR HEALTH. Patients, physicians, the pharmaceutical industry and the NHS. Február 2009. Správa pracovného tímu.
2. Ak máte zmätok ohľadom Európskej agentúry pre liečivá britského MHRA a toho, aký vzťah medzi sebou vlastne majú, je to úplne jednoduché. MHRA schvaľoval lieky skôr, EMA ich schvaľuje teraz. Niektorú miestnu prácu však odovzdala starším národným regulátorom, obzvlášť dohľad a komunikáciu, rovnako ako časť schvaľovacieho personálu.
3. Odporúčam prácu Johna Abrahama, stiahnuteľnú na:http://www.sussex.ac.uk/profiles/6
4. Owen B. M., Braeutigam R. The Regulation Game: Strategic Use of the Administrative Process. Ballinger Pub Co; 1978. Cez Abraham J. On the prohibition of conflicts of interest in pharmaceutical regulation: Precautionary limits and permissive challenges. Komentár v Sismondo (66:9, 2008, 1909–14) a O'Donovan and Lexchin. Social Science & Medicine. Marec 2010; 70(5):648–51.
5. http://www.alter-eu.org/sites/default/files/documents/lonngren-doc.pdf
6. http://www.alter-eu.org/sites/default/files/documents/lonngren-doc.pdf
7. http://www.alter-eu.org/fr/press-releases/2011/02/25/conflict-of-interest-case-involving-ex-ema-director
8. http://www.corporateeurope.org/publications/block-revolving-door
9. Lurie, P., Almeida, C., Stine, N., Stine, A. R., & Wolfe, S. M. (2006). Financial conflict of interest disclosure and voting patterns at food and drug administration drug advisory committee meetings. JAMA, 295, 1921e1928.

10. Ak vás táto téma zaujíma a chcete sa do nej pustiť hlbšie, nasledujúce odkazy sú dobré miesta, kde môžete začať: http://www.nytimes.com/2009/09/25/health/policy/25knee.html?_r=1; http://www.nytimes.com/2005/02/25/politics/25fda.html. A vynikajúca je tiež práca Projekt o vládnom dozore, vedená vedcom, ktorý pracoval na správach senátora Grassleya o farmaceutickom priemysle: http://www.pogo.org/investigations/public-health/fda.html; http://pogoblog.typepad.com/pogo/2011/08/fdas-janet-woodcock-the-substance-behind-her-non-substantive-substantive-ties-to-industry.html
11. Light D., editor. The Risks of Prescription Drugs (A Columbia/SSRC Book. Columbia University Press; 2010).
12. Survey of FDA Scientists Shows They Feel Pressure to Exclude…: Oncology Times [Internet]. [citované 6. mája 2012]. Dostupné na: http://journals.lww.com/oncology-times/Fulltext/2006/08250/Survey_of_FDA_Scientists_Shows_They_Feel_Pressure.8.aspx
13. USATODAY.com – Survey: FDA scientists question safety [Internet]. [citované 6. mája 2012]. Dostupné na: http://www.usatoday.com/news/health/2004-12-16-fda-survey-usat_x.htm
14. European Journal of Clinical Pharmacology 2011 10.1007/s00228-011-1052-1 Anything new in EU pharmacovigilance? Silvio Garattini and Vittorio Bertele'.
15. Goldberg N. H., Schneeweiss S., Kowal M. K., Gagne J. J. Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States. JAMA: The Journal of the American Medical Association. 4. máj 2011; 305(17):1786–9.
16. Bertele' V., Banzi R., Gluud C., Garattini S. EMA's reflection on placebo does not reflect patients' interests. European Journal of Clinical Pharmacology [Internet]. 2. december 2011 [citované 13. februára 2012]; Epub pred tlačou. Dostupné na: http://www.springerlink.com/content/4j733734v35381jk/
17. Garattini S., Chalmers I. Patients and the public deserve big changes in evaluation of drugs. BMJ. 31. marec 2009; 338(mar313):b1025–b1025.
18. Van Luijn J. C. F., Gribnau F. W. J., Leufkens H. G. M. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. Br J Clin Pharmacol. 2007; 63(2):159–162.
19. Stafford R. S., Wagner T. H., Lavori P. W. New, but Not Improved? Incorporating Comparative-Effectiveness Information into FDA Labeling. N Engl J Med. 12. august 2009; NEJMp0906490.

20. Echt D. S., Liebson P. R., Mitchell L. B., Peters R. W., Obias-Manno D., Barker A. H., et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. Marec 1991; 324(12):781–788.
21. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. Apríl 2000; 283(15):1967–1975.
22. Lenzer J. Spin doctors soft pedal data on antihypertensives. BMJ. 18. január 2003; 326(7381):170.
23. Vilsboll T., Christensen M., Junker A. E., Knop F. K., Gluud L. L. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 11. január 2012; 344(jan10 2):d7771–d7771.
24. Grimes D. A., Schulz K. F. Surrogate end points in clinical research: hazardous to your health. Obstet Gynecol 2005;105:1114–8.
25. Tento graf pochádza zo 7. kapitoly vynikajúcich (aj keď dlhých a vážnych) dejín FDA: Carpenter D. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton University Press; 2010.
26. Mitka M. FDA Takes Slow Road Toward Withdrawal of Drug Approved With Fast-Track Process. JAMA. 9. marec 2011; 305(10):982–4.
27. Press Announcements > FDA Proposes Withdrawal of Low Blood Pressure Drug [Internet]. [citované 7. mája 2012]. Dostupné na: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm222580.htm
28. United States Government Accountability Office. Október 2009. NEW DRUG APPROVAL. FDA Needs to Enhance Its Oversight of Drugs Approved on the Basis of Surrogate Endpoints. http://www.gao.gov/new.items/d09866.pdf
29. Davis C., Abraham J. Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation. Sociology of Health & Illness. 1. júl 2011; 33(5):731–47.
30. Barbui C., Cipriani A., Lintas C., Bertel V., Garattini S. CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation? Psychopharmacology. 22. november 2006; 190(2):265–8.
31. Existuje dobré, bezplatné zhrnutie otázok z tejto oblasti v PDF od Svetovej zdravotníckej organizácie: Aidan Hollis. Me Too Drugs: is there

a problem? http://www.who.int/intellectualproperty/topics/ip/Me-tooDrugs_Hollis1.pdf

32. NICE, 'CG17 Dyspepsia: full guideline,' Guidance/Clinical Guidelines, http://guidance.nice.org.uk/CG17/Guidance/pdf/English. Ak by vám smernice NICE a jeho odkazy nestačili (pochádzajú z roku 2004), venujte prosím hodinku svojho času štúdiu ďalších novších výskumov. Zistíte, že na Esomeprazole nebolo nájdené nič magické.
33. http://www.nytimes.com/2004/10/12/business/media/12drug.html
34. http://www.mediapost.com/publications/?fa=Articles.showArticle&art_aid=92473
35. http://www.forbes.com/forbes/2010/0412/opinions-healthcare-nexium-hmo-prescriptions-heads-up.html
36. Tu by som mal priznať svoj záujem: sedím vo finančnej rade, ktorá rieši presne túto otázku každé štyri roky pre program NHS „Hodnotenie zdravotníckej technológie". Tento prúd financovania je špeciálne určený na odhaľovanie výskumov, ktoré je potrebné urobiť, ale ktoré nebude financovať žiadna firma, na porovnanie jedných liekov s inými. Ak ste si vedomí nejakých významných oblastí, kde nevieme, ktorý z dvoch známych liekov je lepší, mali by ste si tu podať žiadosť (alebo ak ste leniví, napíšte mi e-mail).
37. Ak vás veľmi zaujíma táto téma, v tomto detaile spočíva vážny problém. Medzinárodná spoločnosť bulletinov o liekoch, ktorá zastupuje akademikov a farmaceutov vytvárajúca prívetivé zhrnutie údajov pre lekárov, počas piatich rokov viedla kampaň za to, aby získala prístup k niečomu menom Signal, publikácii WHO, ktorá hovorí o otázkach bezpečnosti lieku, ktoré vzišli z nespracovaných údajov z kazuistík. WHO neustále odmietala a trvala na tom, že správu môžu vidieť len „národné zdravotnícke úrady", ale v roku 2012 zmenila názor a teraz plánuje širší prístup aj pre iné nezávislé skupiny. Tým však sága bohužiaľ nekončí. Farmaceutickým firmám sa stále povoľuje prvotný prístup, aby mohli „čítať a komentovať" pred publikáciou. A Signal je len publikácia popisujúca výsledky, nie jednotlivé prípadové štúdie, ktoré sú zhromaždené v tzv. VigiBase, ktorá naďalej zostáva tajná. Údaje z UK a USA sú ľahšie dostupné, ale údaje EÚ, ako asi čakáte, nie. Viac si môžete prečítať v tlačovej správe a na webovej stránke ISDB: http://www.isdbweb.org/publications/view/pharmacovigilance-data ('Broadening access to signal is a positive step, but access to VigiBase is also needed', ISDB, 15. február 2012).

38. Hazell L., Shakir S. A. W. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 2006; 29(5):385–96.
39. L. Härmark a A. C. Grootheest, 'Pharmacovigilance: methods, recent developments and future perspectives,' European Journal of Clinical Pharmacology 64, no. 8 (4. jún 2008): 743–752.
40. FDA warns Pfizer for not reporting side effects – Reuters [Internet]. [citované 8. mája 2012]. Dostupné na: http://www.reuters.com/article/2010/06/10/us-pfizer-fda-idUSTRE6586PE20100610
41. Healy D.: Let them eat Prozac. New York: New York University Press; 2004. Furukawa TA: All clinical trials must be reported in detail and made publicly available. BMJ 2004, 329:626. Via Gøtzsche P. C. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials. 23. november 2011; 12(1):249.
42. Serena Frau et al., 'Risk Management Plans: are they a tool for improving drug safety?,' European Journal of Clinical Pharmacology 66, no. 8 (25. jún 2010): 785–790.
43. Giezen T. J., Mantel-Teeuwisse A. K., Straus S. M. J. M., Egberts T. C. G., Blackburn S., Persson I., et al. Evaluation of post-authorization safety studies in the first cohort of EU Risk Management Plans at time of regulatory approval. Drug Saf. 2009; 32(12):1175–87.
44. Andrew Herxheimer, 'Looking at EU pharmacovigilance,' European Journal of Clinical Pharmacology 67, no. 11 (november 2011): 1201–1202.
45. Schwartz L. M., Woloshin S. Communicating Uncertainties About Prescription Drugs to the Public: A National Randomized Trial. Arch Intern Med. 12. september 2011; 171(16):1463–8.
46. EMA Press Office, 2. február 2012, EMA/30803/2012
47. Garattini S., Bertele' V. Anything new in EU pharmacovigilance? Eur. J. Clin. Pharmacol. november 2011; 67(11):1199–200.
48. Garattini S., Bertele' V. (2010) Rosiglitazone and the need for a new drug safety agency. Br Med J 341:c5506. doi:10.1136/bmj.c5506
49. http://www.nap.edu/catalog.php?record_id=11750#orgs
50. http://www.iom.edu/Reports/2006/The-Future-of-Drug-Safety-Promoting-and-Protecting-the-Health-of-the-Public.aspx
51. Carpenter D. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton University Press; 2010.
52. European Journal of Clinical Pharmacology 2011 10.1007/s00228-011-1052-1 Anything new in EU pharmacovigilance? Silvio Garattini1 and Vittorio Bertele'1

53. Uncommon knowledge. Drug and Tuerapautics Bulletin. 1. november 2009; 47(11):121
54. Schwartz L. M., Woloshin S., Welch H. G. Using a Drug Facts Box to Communicate Drug Benefits and Harms Two Randomized Trials. Ann Intern Med. 21. apríl 2009; 150(8):516–27.
55. Germany's tough reimbursement rules cause drug companies to consider alternative drug trial solutions – FT.com [Internet]. [citované 15. februára 2012]. Dostupné na: http://www.ft.com/cms/s/2/d458d470-4696-11e1-89a8-00144feabdc0.html#axzz1mTzZ2jdb.

4. kapitola: Podivné výskumy

1. Anesthesiology News – Fraud Case Rocks Anesthesiology Community [Internet]. [citované 12. februára 2012]. Dostupné na: http://www.anesthesiologynews.com/ViewArticle.aspx?d=Policy per cent2B per cent26amp per cent3B percent2BManagement&d_id=3&i=March percent2B2009&i_id=494&a_id=12634&ses=ogst
2. Tento príbeh je dobre popísaný v knihe Wellse F.: Fraud and Misconduct in Biomedical Research. 5. kapitola, štvrté vd. RSM Books; 2008. Vrelo vám odporúčam túto knihu, ak sa chcete dostať do odhaľovania a práce s podvodmi. Ale pozor, je to kniha akademická, a teda nechutne drahá.
3. Rothwell P. M. External validity of randomised controlled trials: 'To whom do the results of this trial apply?' The Lancet. 1. január 2005; 365(9453):82–93.
4. Pratt, C. M. & Moye, L. A., 1995. The Cardiac Arrhythmia Suppression Trial : Casting Suppression in a Different Light. Circulation, 91(1), str. 245–247.
5. Travers, J. et al., 2007. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax, 62(3), str. 219 –223.
6. Zimmerman, M., Chelminski, I. & Posternak, M. A., 2004. Exclusion criteria used in antidepressant efficacy trials: consistency across studies and representativeness of samples included. The Journal of Nervous and Mental Disease, 192(2), str. 87–94.
7. Keitner, G. I., Posternak, M. A. & Ryan, C. E., 2003. How many subjects with major depressive disorder meet eligibility requirements of

an antidepressant efficacy trial? The Journal of Clinical Psychiatry, 64(9), str. 1091–3.
8. Jarvinen T. L. N., Sievanen H., Kannus P., Jokihaara J., Khan K. M. The true cost of pharmacological disease prevention. BMJ. 19. apríl 2011; 342(apr19 1):d2175–d2175.
9. Van Staa T.-P., Leufkens H. G., Zhang B., Smeeth L. A Comparison of Cost Effectiveness Using Data from Randomized Trials or Actual Clinical Practice: Selective Cox-2 Inhibitors as an Example. PLoS Med. 8. december 2009; 6(12):e1000194.
10. Safer D. J. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J. Nerv. Ment. Dis. september 2002; 190(9):583–92.
11. Califf R. M., DeMets D. L. Principles From Clinical Trials Relevant to Clinical Practice: Part I. Circulation. 20. august 2002; 106(8):1015–21.
12. Mueller P. S., Montori V. M., Bassler D., Koenig B. A., Guyatt G. H. Ethical Issues in Stopping Randomized Trials Early Because of Apparent Benefit. Annals of Internal Medicine. 19. jún 2007; 146(12):878–881.
13. Bassler D., Briel M., Montori V. M., Lane M., Glasziou P., Zhou Q. et al. Stopping Randomized Trials Early for Benefit and Estimation of Treatment Effects: Systematic Review and Meta-regression Analysis. JAMA. 24. marec 2010; 303(12):1180–7.
14. Montori V. M., Devereaux P. J., Adhikari N. K. J., Burns K. E. A., Eggert C. H., Briel M., et al. Randomized Trials Stopped Early for Benefit: A Systematic Review. JAMA. 2. november 2005; 294(17):2203–9.
15. Trotta F., Apolone G., Garattini S., Tafuri G. Stopping a trial early in oncology: for patients or for industry? Annals of Oncology [Internet]. 1. január 2008 [citované 14. februára 2012]; Dostupné na: http://annonc.oxfordjournals.org/content/early/2008/04/09/annonc.mdn042.full
16. Lurie P., Wolfe S. M. Misleading data analyses in salmeterol (SMART) study. The Lancet. október 2005; 366(9493):1261–2.
17. Rickard K. A. Misleading data analyses in salmeterol (SMART) study – GlaxoSmithKline's reply. The Lancet. október 2005; 366(9493):1262.
18. Garcialopez F., Dealvaro F. INSIGHT and NORDIL. The Lancet. 2. december 2000; 356(9245):1926–1926.
19. Safer D. J. Design and reporting modifications in industry-sponsored comparative psychopharmacology trials. J. Nerv. Ment. Dis. september 2002; 190(9):583–92.

20. Gilbody S., Wahlbeck K., Adams C. Randomized controlled trials in schizophrenia: a critical perspective on the literature. Acta Psychiatr Scand. 2002; 105:243–251.
21. Montori V. M., Jaeschke R., Schünemann H. J., Bhandari M., Brozek J. L., Devereaux P. J., et al. Users' guide to detecting misleading claims in clinical research reports. BMJ. 6. november 2004; 329(7474):1093–6.
22. Shaughnessy A. F., Slawson D. C. What happened to the valid POEMs? A survey of review articles on the treatment of type 2 diabetes. BMJ. 2. august 2003; 327(7409):266.
23. Melander H., Ahlqvist-Rastad J., Meijer G., Beermann B. Evidence b(i) ased medicine – selective reporting from studies sponsored by pharmaceutical industry: review of studies in new drug applications. BMJ 2003; 326:1171–3.
24. Vedula, S. Swaroop, Lisa Bero, Roberta W. Scherer a Kay Dickersin. 'Outcome reporting in industry-sponsored trials of gabapentin for off-label use.' The New England Journal of Medicine 361, no. 20 (12. november 2009): 1963–1971.
25. Chan A.-W., Hróbjartsson A., Haahr M. T., Gøtzsche P. C., Altman D. G.: Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004, 291:2457–2465.
26. Jon N. Jureidini, Leemon B. McHenry, Peter R. Mansfield. Clinical trials and drug promotion: Selective reporting of study 329. International Journal of Risk & Safety in Medicine 20 (2008) 73–81 73 DOI 10.3233/JRS-2008-0426
27. K. L. Lee et al., 'Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease,' Circulation 61, no. 3 (marec 1980): 508–15.
28. V oblasti analýzy podskupín môžem odporúčať tento vynikajúci revízny článok Petera Rothwella z roku 2005: Rothwell P. M. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. The Lancet. 2005; 365(9454):176–86. V súčasnosti voľne dostupné on-line na http://apps.who.int/rhl/Lancet_365-9454.pdf
29. EuropeanCarotidSurgeryTrialists'CollaborativeGroup. Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet 1998; 351: 1379–87.

30. The Canadian Cooperative Study Group. A randomised trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299: 53–59.
31. Ioannidis J. P. A., Karassa F. B. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. BMJ. september 2010; 341(sep131):c4875–c4875.
32. Hill K. P., Ross J. S., Egilman D. S., Krumholz H. M. The ADVANTAGE Seeding Trial: A Review of Internal Documents. Annals of Internal Medicine. 2008; 149(4):251–8.
33. Sox H. C., Rennie D. Seeding Trials: Just Say "No." Annals of Internal Medicine. 2008; 149(4):279–80.
34. Krumholz S. D., Egilman D. S., Ross J. S. Study of Neurontin: Titrate to Effect, Profile of Safety (STEPS) Trial: A Narrative Account of a Gabapentin Seeding Trial. Arch Intern Med. 27. jún 2011; 171(12):1100–7.
35. Odporúčam túto knihu ako úvod do „zdieľaného rozhodovania" (spolupracoval som na jednej kapitole): Gigerenzer G, Muir G. Better Doctors, Better Patients, Better Decisions: Envisioning Health Care 2020. 1st ed. MIT Press; 2011.
36. Malenka D. J., Baron J. A., Johansen S., Wahrenberger J. W., Ross J. M. The framing effect of relative and absolute risk. J Gen Intern Med. október 1993; 8(10):543–8.
37. Bucher H. C., Weinbacher M., Gyr K. Influence of method of reporting study results on decision of physicians to prescribe drugs to lower cholesterol concentration. BMJ. 24. september 1994; 309(6957):761–4.
38. Fahey T., Griffiths S., Peters T. J. Evidence based purchasing: understanding results of clinical trials and systematic reviews. BMJ. 21. október 1995; 311(7012):1056–9.
39. Express.co.uk New wonder heart pill that may save millions [Internet]. [citované 12. februára 2012]. Dostupné na: http://www.express.co.uk/posts/view/70343
40. Drug could save thousands from heart attacks – Science – The Guardian [Internet]. [citované 12. februára 2012]. Dostupné na: http://www.guardian.co.uk/science/2008/nov/10/drugs-medical-research
41. Boutron I., Dutton S., Ravaud P., Altman D. G. Reporting and Interpretation of Randomized Controlled Trials With Statistically Nonsignificant Results for Primary Outcomes. JAMA. 26. máj 2010; 303(20):2058–64.
42. Alasbali, T. et al., 2009. Discrepancy between results and abstract conclusions in industry – vs nonindustry-funded studies comparing

topical prostaglandins. American Journal of Ophthalmology, 147(1), str. 33–38.e2.
43. Jørgensen A. W., Hilden J., Gøtzsche P. C. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ. 14. október 2006; 333(7572):782.

5. kapitola: Väčšie a jednoduchšie výskumy

1. Staa T.-P. v., Goldacre B., Gulliford M., Cassell J., Pirmohamed M., Taweel A., et al. Pragmatic randomised trials using routine electronic health records: putting them to the test. BMJ. 7. február 2012; 344(feb07 1):e55–e55.
2. Edwards P., Arango M., Balica L., Cottingham R., El-Sayed H., Farrell B., et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury-outcomes at 6 months. Lancet. 4. jún 2005; 365(9475):1957–9.
3. Dresden G. M., Levitt M. A. Modifying a Standard Industry Clinical Trial Consent Form Improves Patient Information Retention as Part of the Informed Consent Process. Academic Emergency Medicine. 2001; 8(3):246–52.

6. kapitola: Marketing

1. Alper B. S., Hand J. A., Elliott S. G., Kinkade S., Hauan M. J., Onion D. K., et al. How much effort is needed to keep up with the literature relevant for primary care? J Med Libr Assoc 2004; 92:429–37
2. Moon J. C., Flett A. S., Godman B. B., Grosso A. M., Wierzbicki A. S. Getting better value from the NHS drug budget. BMJ. 17. december 2010; 341(dec17 1):c6449–c6449.
3. Utrácanie za marketing je veľmi popieraná oblasť, pretože priemysel sa to stále snaží bagatelizovať. Odporúčam vám nasledujúci článok, pretože je k nemu voľný prístup a ponúka zhŕňajúce čísla a metódy, z ktorých bol vyvodený, taktiež ako kritickú diskusiu o iných odhadoch: Gagnon M.-A., Lexchin J. The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States. PLoS Med. 3. január 2008; 5(1):e1.

4. Gilbody S., Wilson P., Watt I. Benefits and harms of direct to consumer advertising: a systematic review. Quality and Safety in Health Care. 2005; 14(4):246–50.
5. Kravitz R. L., Epstein R. M., Feldman M. D., Franz C. E., Azari R., Wilkes M. S., et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 27. apríl 2005; 293(16):1995–2002.
6. Iizuka T. What Explains the Use of Direct-to-Consumer Advertising of Prescription Drugs? The Journal of Industrial Economics. 2004; 52(3):349–79.
7. NICE. CG17 Dyspepsia: full guideline [Internet]. [citované 4. januára 2011]. Dostupné na: http://guidance.nice.org.uk/CG17/Guidance/pdf/English
8. Law M. R., Soumerai S. B., Adams A. S., Majumdar S. R. Costs and Consequences of Direct-to-Consumer Advertising for Clopidogrel in Medicaid. Arch Intern Med. 23. november 2009; 169(21):1969–74.
9. Príklady Reynoldse, Bacall, Lowe a Serial Mom som po prvýkrát videl tu: Petersen M, str. 32: Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs. Picador; 2009.
10. Eisenberg D. It's an Ad, Ad, Ad World. Time [Internet]. 26. august 2002 [citované 25. marca 2012]; Dostupné na: http://www.time.com/time/magazine/article/0,9171,344045,00.html
11. Stars Profit From Covert Drug Pitches – CBS News [Internet]. [citované 25. marca 2012]. Dostupné na: http://www.cbsnews.com/2100-207_162-520196.html
12. Na rovnakom mieste.
13. Alzheimer's Campaign Piques Public and Media Interest: PR News 21. máj 2001. Dostupné na: http://www.prnewsonline.com/news/4782.html
14. Keidan J. Sucked into the Herceptin maelstrom. BMJ. 6. január 2007; 334(7583):18.
15. Wilson P. M., Booth A. M., Eastwood A., Watt I. S. Deconstructing Media Coverage of Trastuzumab (Herceptin): An Analysis of National Newspaper Coverage. J R Soc Med. 1. marec 2008; 101(3):125–32.
16. The selling of a wonder drug – Science – The Guardian [Internet]. [citované 26. mája 2012]. Dostupné na: http://www.guardian.co.uk/science/2006/mar/29/medicineandhealth.health
17. Tamtiež.

18. Aby to bolo úplne jasné, neexistujú žiadne dôkazy, že by sa nejaká firma zúčastnila propagovania Barbary Mossovej v médiách. Tento prípad jednoducho len ilustruje melodramatickú nevhodnosť spravodajstva o nových liekoch proti rakovine.
19. Castrén E. Is mood chemistry? Nature Reviews Neuroscience. 1. marec 2005; 6(3):241–6.
20. The Pittsburgh Tribune Review (4/2/07)
21. Lacasse J. R., Leo J. Serotonin and Depression: A Disconnect between the Advertisements and the Scientific Literature. PLoS Med. 8. november 2005; 2(12):e392.
22. Petersen M., str. 102: Our Daily Meds: How the Pharmaceutical Companies Transformed Themselves into Slick Marketing Machines and Hooked the Nation on Prescription Drugs. Picador; 2009.
23. Tamtiež.
24. Leo J., Lacasse J. The Media and the Chemical Imbalance Theory of Depression. Society. 19. február 2008; 45(1):35–45.
25. Test bol teraz zmenený; pôvodný list je zachovaný on-line na: WebMD's Depression Test Has Only One (Sponsored) Answer: You're 'At Risk' – CBS News [Internet]. [citované 26. marca 2012]. Dostupné na: http://www.cbsnews.com/8301-505123_162-42844266/webmds-depression-test-has-only-one-sponsored-answer-youre-at--risk/?tag=bnetdomain
26. Ebeling M. 'Get with the Program!': Pharmaceutical marketing, symptom checklists and self-diagnosis. Social Science & Medicine. 2011 Sep; 73(6):825–32.
27. Laumann E. O., Paik A., Rosen R. C. Sexual Dysfunction in the United States Prevalence and Predictors. JAMA. 10. február 1999; 281(6):537–44.
28. THE NATION: BETTER LOVING THROUGH CHEMISTRY; Sure, We've Got a Pill for That – New York Times [Internet]. [citované 27. marca 2012]. Dostupné na: http://www.nytimes.com/1999/02/14/weekinreview/the-nation-better-loving-through-chemistry-sure-we--ve-got-a-pill-for-that.html?pagewanted=all&src=pm
29. Moynihan R. The making of a disease: female sexual dysfunction. BMJ. 2003; 326(7379):45–47.
30. Moynihan R. Company launches campaign to 'counter' BMJ claims. BMJ. 18. január 2003; 326(7381):120.
31. Tiefer L. Female Sexual Dysfunction: A Case Study of Disease Mongering and Activist Resistance. PLoS Med. 11. apríl 2006; 3(4):e178.

32. Tamtiež.
33. Tamtiež.
34. Testosterone Patches for Female Sexual Dysfunction. DTB. 1. marec 2009; 47(3):30–4.
35. Durand M. Pharma's Advocacy Dance [Internet]. Successful Product Manager's Handbook. 2006 [citované 26. marca 2012]. Dostupné na: http://www.pharmexec.com/pharmexec/Articles/Pharmas-Advocacy-Dance/ArticleStandard/Article/detail/377999
36. 11. august 2010 – HAI Europe Research Article – Patient & Consumer Organisations at the EMA: Financial Disclosure & Transparency. Napsala Katrina Perehudoff a Teresa Leonardo Alves. 11. august 2010 – HAI Europe Factsheet – Patient & Consumer Organisations at the EMA: Financial Disclosure & Transparency
37. HAI. The Patient & Consumer Voice and Pharmaceutical Industry Sponsorship [Internet]. [citované 26. marca 2012]. Dostupné na: http://apps.who.int/medicinedocs/en/m/abstract/Js17767en/
38. 'Drug firms bankroll attacks on NHS' Independent, 1. október 2008.
39. 'Analysis: Are patient protests being manipulated?' Independent, 1. október 2008.
40. Health chief attacks drug giants over huge profits – UK news – The Observer [Internet]. [citované 26. marca 2012]. Dostupné na: http://www.guardian.co.uk/uk/2008/aug/17/pharmaceuticals.nhs
41. Spurling G. K., Mansfield P. R., Montgomery B. D., Lexchin J., Doust J., Othman N., et al. Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. PLoS Med. 19. október 2010; 7(10):e1000352.
42. Azoulay P. Do pharmaceutical sales respond to scientific evidence? Journal of Economics & Management Strategy. 2002; 11(4):551–94.
43. Heimans L., van Hylckama Vlieg A., Dekker F. W. Are claims of advertisements in medical journals supported by RCTs? Neth J Med. Január 2010; 68(1):46–9.
44. Villanueva P., Peiro S., Librero J., Pereiro I. Accuracy of pharmaceutical advertisements in medical journals. The Lancet. Január 2003; 361(9351):27–32.
45. Spielmans G. I., Thielges S. A., Dent A. L., Greenberg R. P. The accuracy of psychiatric medication advertisements in medical journals. J. Nerv. Ment. Dis. Apríl 2008; 196(4):267–73.
46. Van Winkelen P., van Denderen J. S., Vossen C. Y., Huizinga T. W. J., Dekker F. W., for the SEDUCE study group. How evidence-based are

advertisements in journals regarding the subspecialty of rheumatology? Rheumatology. 1. september 2006; 45(9):1154–7.
47. Othman N., Vitry A., Roughead E. E. Quality of Pharmaceutical Advertisements in Medical Journals: A Systematic Review. PLoS ONE. 22. júl 2009; 4(7):e6350.
48. Gibson L. UK government fails to tackle weaknesses in drug industry. BMJ. 10. september 2005; 331(7516):534–40.
49. Wilkes M. S., Kravitz R. L. Policies, practices, and attitudes of North American medical journal editors. J Gen Intern Med. august 1995; 10(8):443–50.
50. Via: Cooper R. J., Schriger D. L., Wallace R. C., Mikulich V. J., Wilkes M. S. The Quantity and Quality of Scientific Graphs in Pharmaceutical Advertisements. J Gen Intern Med. Apríl 2003; 18(4):294–7. 'Polling of the audience occurred as part of the discussion of the oral presentation of this abstract'. FOURTH INTERNATIONAL CONGRESS ON PEER REVIEW [Internet]. Dostupné na: http://www.ama-assn.org/public/peer/prc_program2001.htm#ABSTRACTS.
51. Môžete si tiež vychutnať niektoré knihy napísané vyslúženými farmaceutickými reprezentantmi, ako napríklad: Reidy J. Hard Sell: The Evolution of a Viagra Salesman. 1st ed. Andrews McMeel Publishing; 2005.
52. Rockoff JD. Drug Reps Soften Their Sales Pitches. Wall Street Journal [Internet]. 10. január 2012 [citované 22. marca 2012]; Dostupné na: http://online.wsj.com/article/SB10001424052970204331304577142763014776148.html
53. Fugh-Berman A., Ahari S. Following the Script: How Drug Reps Make Friends and Influence Doctors. PLoS Med. Apríl 2007; 4(4).
54. Soyk, C., B. Pfefferkorn, P. McBride a R. Rieselbach. 2010. Medical student exposure to and attitudes about pharmaceutical companies. World Medical Journal 109: 142–148.
55. Fischer M. A., Keough M. E., Baril J. L., Saccoccio L., Mazor K. M., Ladd E., et al. Prescribers and Pharmaceutical Representatives: Why Are We Still Meeting? J Gen Intern Med. Júl 2009; 24(7):795–801.
56. Morgan M. A., Dana J., Loewenstein G., Zinberg S., Schulkin J. Interactions of doctors with the pharmaceutical industry. J Med Ethics. Október 2006; 32(10):559–63.
57. B. Hodges, 'Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks,' CMAJ:

Canadian Medical Association Journal = Journal De l'Association Medicale Canadienne 153, no. 5 (1. september 1995): 553–559.
58. Spurling G. K., Mansfield P. R., Montgomery B. D., Lexchin J., Doust J., Othman N., et al. Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. PLoS Med. 19. október 2010; 7(10):e1000352.
59. M. M. Chren a C. S. Landefeld, 'Physicians' behavior and their interactions with drug companies. A controlled study of physicians who requested additions to a hospital drug formulary,' JAMA: The Journal of the American Medical Association 271, no. 9 (2. marec 1994): 684–689.
60. Ladd E. C., Mahoney D. F., Emani S. 'Under the radar': nurse practitioner prescribers and pharmaceutical industry promotions. Am J Manag Care. 2010; 16(12):e358–362.
61. Zipkin D. A., Steinman M. A. Interactions Between Pharmaceutical Representatives and Doctors in Training. J Gen Intern Med. August 2005; 20(8):777–86.
62. Spingarn R. W., Berlin J. A., Strom B. L. When pharmaceutical manufacturers' employees present grand rounds, what do residents remember? Acad Med. Január 1996; 71(1):86–8.
63. Wazana A. Physicians and the Pharmaceutical Industry: Is a Gift Ever Just a Gift? JAMA. 19. január 2000; 283(3):373–80.
64. Lurie N., Rich E. C., Simpson D. E., Meyer J., Schiedermayer D. L., Goodman J. L., et al. Pharmaceutical representatives in academic medical centers: interaction with faculty and housestaff. J Gen Intern Med. Jún 1990; 5(3):240–3.
65. Fugh-Berman A., Ahari S. Following the Script: How Drug Reps Make Friends and Influence Doctors. PLoS Med. Apríl 2007; 4(4).
66. Tamtiež.
67. Sismondo S. How pharmaceutical industry funding affects trial outcomes: Causal structures and responses. Social Science & Medicine. 2008; 66(9):1909–14.
68. Completed Cases – PMCPA Website [Internet]. [citované 26. marca 2012]. Dostupné na: http://www.pmcpa.org.uk/?q=node/868
69. Completed Cases – PMCPA Website [Internet]. [citované 26. marca 2012]. Dostupné na: http://www.pmcpa.org.uk/?q=node/883
70. Orlowski J. P., Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There's no such thing as a free lunch. Chest. Júl 1992; 102(1):270–3.

71. Steinbrook R. For sale: physicians' prescribing data. N. Engl. J. Med. 29. jún 2006; 354(26):2745–7.
72. Physician Data Restriction Program (PDRP) [Internet]. [citované 22. marca 2012]. Dostupné na: http://www.ama-assn.org/ama/pub/about-ama/physician-data-resources/ama-database-licensing/amas-physician-data-restriction-program.page
73. Outterson K. Higher First Amendment Hurdles for Public Health Regulation. New England Journal of Medicine. 18. august 2011; 365(7):e13.
74. Zipkin D. A., Steinman M. A. Interactions Between Pharmaceutical Representatives and Doctors in Training. J Gen Intern Med. August 2005; 20(8):777–86.
75. Wislar J. S., Flanagin A., Fontanarosa P. B., DeAngelis C. D. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 25. október 2011; 343(oct251):d6128–d6128.
76. Gøtzsche P. C., Hróbjartsson A., Johansen H. K., Haahr M. T., Altman D. G., Chan A.-W. Ghost Authorship in Industry-Initiated Randomised Trials. PLoS Med. 16. január 2007; 4(1):e19.
77. 'Ghost writing in the medical literature' 111th Congress, United States Senate Committee on Finance Sen. Charles E. Grassley, 2010. [citované 24. marca 2012]. Dostupné na: http://www.grassley.senate.gov/about/upload/Senator-Grassley-Report.pdf
78. Richard Horton PI 108, House of Commons – Health – Minutes of Evidence [Internet]. [citované 24. marca 2012]. Dostupné na: http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/4121604.htm
79. Galanter M., Galanter M., Felstiner W. L. F., Friedman L. M., Girth M., Goldstein P., et al. Why the haves come out ahead: Speculations on the limits of legal change. Law Society Review. 1974; 9:95–169.
80. Lilly 'Ghostwrote' Articles to Market Drug, Files Say (Update2) Bloomberg [Internet]. [citované 24. marca 2012]. Dostupné na: http://www.bloomberg.com/apps/news?pid=newsarchive&sid=a6yFu_t9NyTY
81. http://www.psychiatrynorthwest.co.uk/general_adult_psychiatry/spr_posts/salford-haddad/index.html
82. Medical Press Pre-Launch Feature Outline, Zyprexa MDL 1596, confidential subject to protection order ZY200187608. http://zyprexalitigationdocuments.com/per cent5Cdocuments per cent5CConfidentiality-Challenge per cent5CDocs-challenged-in-10-3-list per cent5C145-ZY200187608-7614.pdf

83. Drug Industry Document Archive [Internet]. [citované 24. marca 2012]. Dostupné na: http://dida.library.ucsf.edu/
84. Drug Industry Document Archive – Search Results [Internet]. [citované 24. marca 2012]. Dostupné na: http://dida.library.ucsf.edu/tid/anu38h10
85. Tamtiež.
86. Ross, J. S., K. P. Hill, D. S. Egilman a H. M. Krumholz. 2008. Guest authorship and ghostwriting in publications related to rofecoxib: A case study of industry documents from rofecoxib litigation. Journal of the American Medical Association 299:1800–1812.
87. POGO Letter to NIH on Ghostwriting Academics [Internet]. Project On Government Oversight. [citované 24. marca 2012]. Dostupné na: http://www.pogo.org/pogo-files/letters/public-health/ph-iis-20101129.html
88. http://www.nytimes.com/2010/11/30/business/30drug.html
89. http://pogoblog.typepad.com/pogo/gw-attachment-e.html
90. Lacasse J. R., Leo J. Ghostwriting at Elite Academic Medical Centers in the United States. PLoS Med. 2. február 2010; 7(2):e1000230.
91. Matheson A. How Industry Uses the ICMJE Guidelines to Manipulate Authorship – And How They Should Be Revised. PLoS Med. 2011; 8(8):e1001072.
92. Dyer O. Journal rejects article after objections from marketing department. BMJ. 31. január 2004; 328(7434):244–b–244.
93. Fugh-Berman A., Alladin K., Chow J. Advertising in Medical Journals: Should Current Practices Change? PLoS Med. 2. máj 2006; 3(6):e130.
94. Becker A., Dörter F., Eckhardt K., Viniol A., Baum E., Kochen M. M., et al. The association between a journal's source of revenue and the drug recommendations made in the articles it publishes. CMAJ. 28. február 2011 Dostupné na: http://www.cmaj.ca/content/early/2011/02/28/cmaj.100951
95. Smith R. Medical Journals Are an Extension of the Marketing Arm of Pharmaceutical Companies. PLoS Med. 17. máj 2005; 2(5):e138.
96. AUTH/2424/8/11 and AUTH/2425/8/11 – General Practitioner v Boehringer Ingelheim and Lilly. Dostupné na: http://www.pmcpa.org.uk/?q=node/998.
97. Handel A. E., Patel S. V., Pakpoor J., Ebers G. C., Goldacre B., Ramagopalan S. V. High reprint orders in medical journals and pharmaceutical industry funding: case-control study. BMJ. 28. jún 2012; 344(jun28 1):e4212–e4212.

98. Jefferson T., Di Pietrantonj C., Debalini M. G., Rivetti A., Demicheli V. Relation of study quality, concordance, take home message, funding, and impact in studies of influenza vaccines: systematic review. BMJ. 12. február 2009; 338(feb12_2):b354.
99. http://classic.the-scientist.com/blog/display/55679/
100. http://elsevier.com/wps/find/authored-_newsitem.cws_home/companynews05_01203
101. Bowman M. A. The impact of drug company funding on the content of continuing medical education. Möbius: A Journal for Continuing Education Professionals in Health Sciences. 1. január 1986; 6(1):66–9.
102. Bowman M. A., Pearle D. L. Changes in drug prescribing patterns related to commercial company funding of continuing medical education. Journal of Continuing Education in the Health Professions. 1. január 1988; 8(1):13–20.
103. The Carlat Psychiatry Blog: PRMS [Internet]. [citované 31. marca 2012]. Dostupné na: http://carlatpsychiatry.blogspot.co.uk/search/label/PRMS
104. Stephan Sahm, 'Of mugs, meals and more: the intricate relations between physicians and the medical industry.,' Medicine, health care, and philosophy (2011).
105. Avorn J., Choudhry N. K. Funding for Medical Education: Maintaining a Healthy Separation From Industry. Circulation. 25. máj 2010; 121(20):2228–34.
106. L. Garattini et al., 'Continuing Medical Education in six European countries: A comparative analysis,' Health policy 94, no. 3 (2010): 246–254.
107. Eckardt V. F. Complimentary journeys to the World Congress of Gastroenterology – an inquiry of potential sponsors and beneficiaries. Z Gastroenterol. Január 2000; 38(1):7–11.
108. http://www.pmlive.com/find_an_article/allarticles/categories/General/2011/november_2011/features/cme_continuing_medical_education_change
109. US Senate Committee on Finance. Committee Staff Report to the Chairman and Ranking Member: Use of Educational Grants by Pharmaceutical Manufacturers. Washington, DC: Government Printing Office; 2007.
110. Hensley S., Martinez B. To sell their drugs, companies increasingly rely on doctors. Wall St J (East Ed). 15. júl 2005; A1,A2.

111. Tabas J. A., Boscardin C., Jacobsen D. M., Steinman M. A., Volberding P. A., Baron R. B. Clinician Attitudes About Commercial Support of Continuing Medical Education: Results of a Detailed Survey. Arch Intern Med. 9. máj 2011; 171(9):840–6.
112. Amy T. Wang et al., 'Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review,' BMJ 340, no. 18 (18. marec 2010): c1344.
113. Rothman K. J., Evans S. (2005) Extra scrutiny for industry funded trials. BMJ 331: 1350–1351
114. Wager E., Mhaskar R., Warburton S., Djulbegovic B. (2010) JAMA Published Fewer Industry-Funded Studies after Introducing a Requirement for Independent Statistical Analysis. PLoS ONE 5(10): e13591. doi:10.1371/journal.pone.0013591
115. Chalmers T. C., Frank C. S., Reitman D. Minimizing the Three Stages of Publication Bias. JAMA. 9. marec 1990; 263(10):1392–5.
116. Samena Chaudhry et al., 'Does declaration of competing interests affect readers' perceptions? A randomised trial,' BMJ 325, no. 7377 (14. december 2002): 1391–1392. (níže).
117. Reporting of Conflicts of Interest in Meta-analyses of Trials of Pharmacological Treatments. JAMA. 2011; 305(10):1008–1017. doi: 10.1001/jama.2011.257
118. Loewenstein G., Sah S., Cain D. M. The Unintended Consequences of Conflict of Interest Disclosure. JAMA. 15. február 2012; 307(7):669–70.
119. Cain, D. M., Loewenstein, G., & Moore, D. A. (2005). The dirt on coming clean: perverse effects of disclosing conflicts of interest. Journal of Legal Issues, 34, 1e25.
120. Campbell E. G., Weissman J. S., Ehringhaus S. et al. Institutional academic industry relationships. JAMA 2007;298:1779–86.
121. http://www.propublica.org/series/dollars-for-docs
122. http://www.propublica.org/article/doctors-dine-on-drug-companies-dime
123. http://www.propublica.org/article/dollars-for-docs-sparks-policy-rewrite-at-colorado-teaching-hospitals
124. http://www.propublica.org/article/medical-schools-plug-holes-in-conflict-of-interest-policies
125. http://www.propublica.org/article/dollars-to-doctors-physician-disciplinary-records/single
126. http://www.propublica.org/article/drug-companies-reduce-payments-to-doctors-as-scrutiny-mounts

127. http://www.propublica.org/article/piercing-the-veil-more-drug-companies-reveal-payments-to-doctors
128. Carlowe J. Drug companies to declare all payments made to doctors from 2012. BMJ. 5. november 2010; 341(nov051):c6290–c6290.
129. Tuffs A. Two doctors in Germany are convicted of taking bribes from drug company. BMJ. 9. november 2010; 341(nov092):c6359–c6359.
130. http://www.fcaalert.com/2011/02/articles/dojhhs-releases-new-statistics-about-sealed-qui-tam-cases/
131. Sweet M. Experts criticise industry sponsorship of articles on health policy in Australian newspaper. BMJ. 25. október 2011; 343(oct25 2):d6903–d6903.
132. http://www.pmcpa.org.uk/?q=node/499
133. http://www.propublica.org/documents/item/87376-heart-rhythm-society
134. http://www.propublica.org/article/medical-groups-shy-about-detailing-industry-financial-support
135. J. P. Kassirer. On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health. 1st ed. Oxford University Press, USA; 2004.
136. http://www.eatright.org/corporatesponsors/.
137. J. P. Kassirer. On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health. 1st ed. Oxford University Press, USA; 2004, str. 105.
138. Choudhry N. K., Stelfox H. T., Detsky A. S. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 6. február 2002; 287(5):612–7.

Doslov: Lepšie údaje

1. Department of Justice, Office of Public Affairs. GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data. 2. júl 2012. http://www.justice.gov/opa/pr/2012/July/12-civ-842.html
2. Glaxo executives cited in case now lead Sanofi, Actelion. Bloomberg News, 3/7/12. http://www.businessweek.com/news/2012-07-03/glaxo-executives-cited-in-case-now-lead-sanofi-actelion
3. Inpharm 4/7/12. GSK ruling: another failing, but will the industry learn? http://www.inpharm.com/news/173307/gsk-ruling-another-failing-will-industry-learn

4. Glaxo Agrees to Pay $3 Billion in Fraud Settlement. New York Times, 2. júl 2012. http://www.nytimes.com/2012/07/03/business/glaxosmithkline-agrees-to-pay-3-billion-in-fraud-settlement.html
5. Level playing field push to continue despite setback – 8. december 2011. Medicines Australia. http://medicinesaustralia.com.au/2011/12/08/level-playing-field-push-to-continue-despite-setback/
6. Drug companies to work with CCGs on care pathways and case finding under DH-backed scheme. Pulse, 28. máj 2012, http://www.pulsetoday.co.uk/ newsarticle-content/-/article_display_list/14029608/drug-companies-to-work-with-ccgs-on-care-pathways-and-case-finding-under-dh-backed-scheme.
7. Bosch X., Esfandiari B., McHenry L. Challenging Medical Ghostwriting in US Courts. PLoS Med. 24. január 2012; 9(1):e1001163.

Ilustrácie

Obr. 1 (str. 26): http://www.cochrane.org/about-us/history/our-logo%23files
Obr. 2 (str. 28): Mulrow CD. Rationale for systematic reviews. BMJ. 3. september 1994; 309(6954):597–9. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2541393/?page=1;
Obr. 3 (str. 67): Ranibizumab and pegaptanib for the treatment of age--related macular degeneration: a systematic review and economic evaluation. NICE 2006. Dostupné na: http://www.nice.org.uk/nicemedia/live/11700/34991/34991.pdf
Obr. 4 (str. 77): http://www.prescrire.org/editoriaux/EDI33693.pdf
Obr. 6 (str. 126): Carpenter D. Reputation and Power: Organizational Image and Pharmaceutical Regulation at the FDA. Princeton University Press, 2010.
Obr. 7 (str. 150): Schwartz LM, Woloshin S, Welch HG. Using a Drug Facts Box to Communicate Drug Benefits and Harms Two Randomized Trials. Ann Intern Med. 21. apríl 2009; 150(8):516–27. Dostupné na: http://dartmed.dartmouth.edu/spring08/pdf/disc_drugs_we/lunesta_box.pdf
Obr. 8 (str. 151): http://www.lunesta.com/PostedApprovedLabelingText.pdf
Obr. 9 (str. 170): Lurie P, Wolfe SM. Misleading data analyses in salmeterol (SMART) study. The Lancet. Október 2005; 366(9493):1261–2.
Obr. 11 (str. 186): Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. The Lancet.

2005; 365(9454):176–86. Dostupné na: http://apps.who.int/rhl/Lancet_365-9454.pdf

Obr. 12 (str. 229): Moynihan R. The making of a disease: female sexual dysfunction. BMJ. 2003; 326(7379):45–47. Dostupné na: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1124933/table/TN0x95f06b0.0x98eca30/

Obr. 13 (str. 255 hore), obr. 14 (str. 255 dole), obr. 15 (str. 256 hore), obr. 16 (str. 295 dole): http://zyprexalitigationdocuments.com/%5Cdocuments%5CConfidentiality-Challenge%5CDocs-challenged-in-10-3-list%5C145-ZY200187608-7614.pdf

Obr. 17 (str. 256): Drug Industry Document Archive [Internet]. Dostupné na: http://dida.library.ucsf.edu/pdf/vou38h10

Obr. 18 (str. 257): http://pogoblog.typepad.com/pogo/gw-attachment-e.html

Obr. 19 (str. 297): 15. august 2012, http://uk.finance.yahoo.com/echarts?s=GSK.L#symbol=GSK.L;range=1y